Taipei Exchange - Delayed Quote TWD

AnnJi (7754.TWO)

25.20
+0.20
+(0.80%)
At close: May 29 at 2:59:44 PM GMT+8
Loading Chart for 7754.TWO
  • Previous Close 25.00
  • Open 24.90
  • Bid 24.90 x --
  • Ask 25.25 x --
  • Day's Range 24.90 - 25.25
  • 52 Week Range 14.05 - 72.40
  • Volume 65,607
  • Avg. Volume 222,000
  • Market Cap (intraday) 2.358B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -3.81
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy, a neurodegenerative disease; AJ202 for androgenetic alopecia; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. AnnJi Pharmaceutical Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.

www.ajpharm.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 7754.TWO

View more

Performance Overview: 7754.TWO

Trailing total returns as of 5/29/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

7754.TWO
27.69%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
7.33%

1-Year Return

7754.TWO
56.92%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
1.46%

3-Year Return

7754.TWO
56.92%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
31.24%

5-Year Return

7754.TWO
56.92%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
95.09%

Compare to: 7754.TWO

Select to analyse similar companies using key performance metrics; select up to four stocks.

Statistics: 7754.TWO

View more

Valuation Measures

Annual
As of 5/29/2025
  • Market Cap

    2.36B

  • Enterprise Value

    1.71B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    24.32

  • Price/Book (mrq)

    3.57

  • Enterprise Value/Revenue

    17.75

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -20.37%

  • Return on Equity (ttm)

    -44.61%

  • Revenue (ttm)

    96.45M

  • Net Income Avi to Common (ttm)

    -353.99M

  • Diluted EPS (ttm)

    -3.81

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    706.01M

  • Total Debt/Equity (mrq)

    8.36%

  • Levered Free Cash Flow (ttm)

    -78.57M

Research Analysis: 7754.TWO

View more

Company Insights: 7754.TWO

Research reports: 7754.TWO

View more